Dr. Saef Izzy, Associate Professor of Neurology at Harvard Medical School, commented, “Treatment with nasal anti-CD3 not only dampened microglial activation but also led to marked improvements in ...
Tiziana Life Sciences announces positive results from studies using nasal anti-CD3 mAb in traumatic spinal cord injury: New York Saturday, January 25, 2025, 13:00 Hrs [IST] Tizian ...
Tiziana Life Sciences Ltd., which is developing the intranasal fully human anti-CD3 monoclonal antibody foralumab for neurological indications, has reported results from studies using a nasal anti-CD3 ...
Shares of Tiziana Life Sciences rose after the company said it received positive results from its nasal anti-CD3 monoclonal antibody in traumatic spinal cord injury. The stock was up 5.3% to 84 cents ...